[Polo-like Kinase 1 as a Target for Anti-tumor Therapy]

Area of Science:

• Cell Biology
• Molecular Oncology
• Biochemistry

Background:

• Polo-like kinase (Plk) family proteins regulate cell cycle and DNA damage response.
• Plk1, the most studied Plk member, is crucial for mitosis.
• Plk1 deregulation and elevated levels correlate with poor prognosis in various cancers.

Purpose of the Study:

• To explore the therapeutic potential of targeting Plk1 in cancer treatment.
• To discuss the relationship between Plk1 and p53 protein.
• To review current and emerging Plk1 inhibitor strategies.

Main Methods:

• Literature review and analysis of existing research on Plk1.
• Discussion of clinical trial data for Plk1 inhibitors.
• Preclinical evaluation of novel Plk1 targeting strategies.

Main Results:

• Plk1 is a validated target for antitumor drug development.
• Volasertib (BI 6727), an ATP-binding site inhibitor, shows survival benefits in acute myeloid leukemia.
• Newer Plk1 inhibitors targeting the polo-box domain are under preclinical investigation for enhanced specificity.

Conclusions:

• Plk1 is a significant therapeutic target in oncology.
• Targeting Plk1, particularly with specific inhibitors, offers a promising avenue for cancer therapy.
• Further development of Plk1 inhibitors, especially those with improved specificity, is warranted.